Relationship between metabolic parameters and lifestyle factors in type 2 diabetes mellitus: a retrospective analysis
DOI:
https://doi.org/10.18203/2320-6012.ijrms20262173Keywords:
Glycemic control, Gender differences, Diabetic dyslipidemia, Cardiovascular disease risk, Age-related metabolic changes, Atherogenic index of plasmaAbstract
Background: This study examined the correlation between metabolic biomarkers (e.g., fasting blood sugar, HbA1C, cholesterol, creatinine) and lifestyle factors (e.g., smoking, body weight, blood pressure) in pre-diabetes and diabetes patients. We wanted to find patterns that may affect metabolic disorders and cardiovascular disease (CVD) in these populations.
Methods: A medical outpatient department patient and laboratory data was used in a retrospective cross-sectional study. FBS, PPBS, HbA1C, lipid profiles, creatinine levels, urine microalbumin, blood pressure, BMI, and risk factors like smoking were analysed using t-tests, ANOVA, and multivariate regression.
Results: The study found significant lipid abnormalities in diabetic individuals. Patients with diabetes had an average triglyceride level of 286.6 mg/dl. Low HDL levels (averaging 36.3±5.8 mg/dl) were also observed. We also had high LDL levels, which increase the risk of cardiovascular disease. The highest triglyceride (305.80 mg/dl) and VLDL (61.16 mg/dl) levels were found in participants aged 60-70. AIP, a key CVD risk marker, was high in older diabetics (0.80), indicating a strong link between age, dyslipidemia, and cardiovascular risk. Furthermore, smoking worsened these lipid irregularities. Males had higher triglycerides than females (p=0.036), but fasting blood sugar, HbA1C, and LDL did not differ.
Conclusions: Research shows a high prevalence of dyslipidemia in diabetics, characterized by elevated triglycerides, low HDL, and high LDL, all linked to increased CVD risk. Early detection and treatment of lipid issues are crucial, particularly for older adults and smokers, who are more prone to atherosclerotic events.
References
Goldberg IJ. Diabetic Dyslipidemia: Causes and Consequences. J Clin Endocrinol Metab. 2001;86(3):965-71.
Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. Nat Rev Endocrinol. 2009;5:150-9.
Dobiasova M, Frohlich J. The plasma parameter log(TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FERHDL). Clin Biochem. 2001;34(7):583-8.
Millan J, Pintó X, Muñoz A, Zúñiga M, Rubiés-Prat J, Pallardo LF, et al. Lipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention. Vasc Health Risk Manage. 2009;5:757-65.
Abbott RD, Garrison RJ, Wilson PW, Epstein FH, Castelli WP. Joint distribution of lipoprotein cholesterol classes: the Framingham study. Arterioscl Thrombos Vasc Biol. 1983;3(3):260-72.
Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 2004;109(23):2568-72.
Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2005;109(3):433-8.
Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2003;361(9374):2005-16.
Bakhru A, Erlinger TP. Smoking cessation and cardiovascular disease risk factors: Results from the Third National Health and Nutrition Examination Survey. PLoS Med. 2005;2(6):e160.
Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ. 1997;314(7075):1383-9.
Viljoen A, Joshi S, Wierzbicki AS. Diabetic dyslipidemia and risk of cardiovascular disease. In: Holt RIG, Cockram CS, Flyvbjerg A, Goldstein BJ, eds. Textbook of Diabetes. 5th edn. Wiley-Blackwell; 2017:643-652,
Sugden M, Holness M. Pathophysiology of diabetic dyslipidemia: implications for atherogenesis and treatment. Clin Lipidol. 2011;6(4):401-11.
Goldberg IJ. Clinical review 124: diabetic dyslipidemia: causes and consequences. J Clin Endocrinol Metab. 2001;86(3):965-71.
Shen GX. Lipid disorders in diabetes mellitus and current management. Curr Pharm Anal. 2007;3(1):17-24.
Wu L, Parhofer KG. Diabetic dyslipidemia. Metabolism. 2014;63(12):1469-79.